Novan's nitric oxide-releasing cream formulation improves itch in atopic dermatitis

Novan Inc. (Durham, N.C.) reported that 2% SB414 cream led to a ≥3-point improvement on the pruritus numeric rating scale (NRS) in 71% of patients vs. 43% for vehicle control in a Phase Ib trial to treat mild to moderate atopic dermatitis. Novan also said 2% SB414 cream significantly reduced inflammatory pathway biomarkers, and that those reductions were highly correlated to the percent change in Eczema Area Severity Index (EASI) scores.

The double-blind, U.S. trial enrolled 48 patients to receive twice-daily 2% SB414 cream, 6% SB414 cream or vehicle for two weeks...